Medical Crossfire

Welcome to Medical Crossfire

Medical Crossfire is a national health care education program dedicated to improving medical practices and patient care through discussion, debate, and authoritative peer exchange on important clinical issues. Produced by Healthcare First, Medical Crossfire is based on the belief that exposure to differing—and often controversial—opinions, insights, and philosophies fuels learning and understanding among health care professionals.

We strive to surpass the value of traditional educational methods by providing validation, relevance, and practicality through exchange between leading experts.

Phase III Study Showed Rituxan In Combination With Chemotherapy Improved Progression-Free Survival In Patients With Relapsed Chronic Leukemia

Sat, 11 Oct 2008 01:00:00 PDT

Genentech, Inc. (NYSE: DNA) and Biogen Idec (Nasdaq: BIIB) today announced that a global Phase III study of Rituxan® (rituximab) in combination with fludarabine and cyclophosphamide chemotherapy met its primary endpoint of improving progression-free survival (PFS), as assessed by investigators, in patients with previously treated CD20-positive chronic lymphocytic leukemia (CLL) compared to chemotherapy alone. There were no new or unexpected safety signals reported in the study.

Early Data Show Potential For Imatinib To Treat Life-threatening Form Of Pulmonary Artery Disease

Sat, 11 Oct 2008 01:00:00 PDT

An early proof-of-concept study presented shows promising results for imatinib in the treatment of pulmonary arterial hypertension (PAH), a severe, incurable blood vessel disorder.

Boston Scientific To Release Broad Range Of Clinical Trial Data On The Performance Of TAXUS(R) Coronary Stent Systems At TCT 2008

Sat, 11 Oct 2008 00:00:00 PDT

Boston Scientific Corporation (NYSE: BSX) announced the schedule of the Company's major events and press announcements at the Cardiovascular Research Foundation's (CRF) twentieth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, which runs from October 12 to 17 in Washington, D.C.

More News...

High-risk patients with stage 2 HTN (Systolic BP= 160 or higher or Diastolic BP= 100 or higher), evidence-based first line pharmacotherapy is recommended as: ( surveys)